BackPsyence Biomedical Ltd. - Warrants (25/01/2029) Overview

Psyence Biomedical Ltd. - Warrants (25/01/2029) Total Liabilities

Track Psyence Biomedical Ltd. - Warrants (25/01/2029)'s total liabilities ($940K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$943068.00
73.12% YoYΔ $-2.57M vs prior year quarter

Peer average / median

Loading

Psyence Biomedical Ltd. - Warrants (25/01/2029) Total Liabilities History

Loading

Psyence Biomedical Ltd. - Warrants (25/01/2029) vs. peers: Total Liabilities Comparison

Loading

Psyence Biomedical Ltd. - Warrants (25/01/2029) Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Psyence Biomedical Ltd. - Warrants (25/01/2029) (PBMWW) FAQ

The latest total liabilities for PBMWW is $940K as of September 2025. That compares with $3.5M in the prior-year period — down 73.1% year over year. Investors often review this figure alongside Psyence Biomedical Ltd. - Warrants (25/01/2029)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, PBMWW's total liabilities moved from $3.5M to $940K — a 73.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Psyence Biomedical Ltd. - Warrants (25/01/2029)'s operating scale or balance-sheet position.

A total liabilities figure of $940K for PBMWW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting PBMWW's total liabilities ($940K), review year-over-year change from $3.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.